His research interests in bioengineering lie within biomaterials and biotherapeutics, biomechanics, biotribology, and biochemistry. He focuses on articular cartilage and ocular surface lubrication, as well as orthopedic and ophthalmic biomaterial development and characterization for the treatment of diseases. He is also a co-founder of Lubris BioPharma, LLC, a clinical stage biotech startup commercializing the use of recombinant human lubricin for the treatment of arthritis, dry eye, and other diseases. Novartis recently exercised an option to in-license recombinant human lubricin for ophthalmic indications worldwide (outside Europe) including the treatment of dry eye.